Status:
UNKNOWN
Effect Of DAAs For Treatment Of HCV On Normal Kidney
Lead Sponsor:
Assiut University
Conditions:
Antiviral Drug Adverse Reaction
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The aim of the study is to determine the effect of different direct acting antiviral drugs used for treatment of chronic HCV infected patients on normal kidney.
Detailed Description
Hepatitis C virus (HCV) infection is a major health problem. The World Health Organization (WHO) estimated that at least 150-170 million people, approximately 3% of the world's population, are chronic...
Eligibility Criteria
Inclusion
- Both male and female patients with age above 18 years presented with chronic HCV infection (diagnosed by HCV RNA positive) with normal kidney functions, i.e.:
- Normal S.creatinine
- Normal urine analysis (without proteinuria, haematuria or abnormal casts).
- Normal renal sonography.
- and candidate for direct acting antiviral drugs.
Exclusion
- Any chronic HCV patient with known renal disease.
- Patients with abnormal kidney functions, i.e.:
- Abnormal S.creatinine.
- Abnormal urine analysis (with proteinuria, haematuria or abnormal casts).
- Abnormal renal US
- Any other known renal disease (lupus nephritis, diabetic nephropathy).
- Severe co-morbidity as severe heart failure or malignancy.
- Other liver disease (autoimmune hepatitis, HBV, Wilson, ……).
- Decompansated liver disease (ascites, hepatic encephalopathy, …).
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03296930
Start Date
October 1 2017
End Date
October 31 2018
Last Update
September 29 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.